International Business Machines (NYSE:IBM | IBM Price Prediction) looks attractively valued at $268.71, with the setup sharpening on any retest of $260. The stock has pulled back meaningfully from its January peak near $314.84 while the broader market grinds higher, opening a gap between price and fundamentals that has not been this wide in years.
Big Blue runs four segments: Software, Consulting, Infrastructure, and Financing. Software and the IBM Z mainframe franchise drive results; Consulting lags. The selloff coincided with a hawkish shift at the Federal Reserve under Kevin Warsh, accelerating quantitative tightening that compressed multiples across enterprise tech regardless of company-specific execution.
IBM just posted its highest first-quarter free cash flow in a decade, yet the market treats it like a stalled legacy name.
Why the Selloff Looks Like a Gift
Q1 2026 was clean. Revenue of $15.92 billion beat by 1.70%, EPS of $1.91 beat by 5.45%, and free cash flow of $2.22 billion rose 13% YoY. Software grew 11.3%, Infrastructure climbed 15.3% on a 51% surge in IBM Z, and operating income jumped 20.62% YoY.
Valuation is unusually reasonable. Trailing P/E sits at 24, forward P/E at 22, with a 2.44% dividend yield backed by the 31st consecutive year of dividend increases. The generative AI book of business cleared $12.5 billion inception-to-date at the end of 2025, and Consulting GenAI alone has eclipsed $4 billion ARR.
What the Bears Are Pricing In
Warsh’s Fed is leaning into quantitative tightening, and tech multiples are compressing. IBM trades at 7.76x book value with $61.3 billion in total debt after acquisitions including Confluent, so any sustained rate shock hits both the multiple and financing cost.
Consulting grew just 1% constant currency, a soft signal on enterprise discretionary spend. Two Strong Sell ratings sit alongside 7 Holds, and the stock is down 8.09% YTD against a 10.69% gain in the S&P 500. If the AI book stops compounding, the multiple has further to fall.
The Honest Case for Sitting Still
Hold investors can point to the one-month rebound of 22.53% off the lows, suggesting the easiest part of the dip trade is behind. The 200-day moving average of $273.07 sits just above current price as overhead resistance. Recent insider activity skews toward director fee-share grants at $242.39 rather than discretionary open-market buying.
The wait-and-see view: let Q2 confirm whether Consulting accelerates and whether management raises full-year guidance. Until then, collect the dividend and watch.
What the Numbers Actually Say
IBM trades at $268.71 with a market cap of roughly $252.56 billion. The analyst consensus target of $290.89 across 22 covering analysts implies modest upside, with 12 Buy or Strong Buy ratings, 7 Hold ratings, and 2 Strong Sell ratings.
IBM is down 8.09% YTD while the S&P 500 is up 10.69%. Over five years IBM is up 131.55% against the index’s 78.82%.
The Verdict: Why $268 Looks Compelling
At $268.71, IBM screens as undervalued on the fundamentals.
Software and Infrastructure are compounding double-digits, 2026 guidance calls for roughly $1 billion in YoY free cash flow improvement on the $14.73 billion 2025 base, and the GenAI book is a tangible revenue pipeline. Multiple compression from Warsh-era QT, rather than deteriorating fundamentals, explains the stock price.
The risk/reward at $268 skews favorably. The 50-day moving average of $249.15 has flipped into support, and the recent 52-week low of $212.34 represents a tail scenario tied to a full macro break. Accumulation at or below $260 sharpens the asymmetry further.
What invalidates the thesis: Software growth slipping below 10%, the AI book stalling for two consecutive quarters, or Z17 mainframe demand fading after the current refresh cycle. Watch Q2 for Consulting acceleration and any guide raise. IBM is delivering record cash flow and double-digit Software growth at a forward P/E of 22, and the market is selling it for reasons unrelated to the business.
Top Gaining Stocks
Top Losing Stocks